Anupriya Agarwal Lab

Professor @OHSUKnight, A team of motivated scientists studying microenvironmental regulation of pre-leukemic and leukemic cells

[Anupriya Agarwal Lab @LabAgarwal]

We are looking for motivated scientists to join our team @OHSUKnight for a postdoctoral position with Experience in cell signaling & cancer biology to study inflammation role in leukemia evolution. Interested candidates DM/apply👇#Academia #postdoc, #phd Pl spread the words

[Curtis Lachowiez @CLachowiez]

Happy to help lead this study here at @OHSUKnight for our patients and families.

[Anupriya Agarwal Lab @LabAgarwal]

Excited to share that our low-dose Sirolimus study for Adults with RUNX1-FPD is now enrolling @OHSUNews. Thanks for partnership: @OHSUKnight, @CLachowiez, Dr. DiNardo, @RUNX1Research @AmericanCancer. Pl share with eligible individuals. https:/clinicaltrials.gov/study/NCT07844694

[RUNX1 Research Program @RUNX1Research]

The low-dose sirolimus pilot study has expanded to @OHSUNews in Portland, with a limited number of additional spots also available at @UTMDAnderson. The expansion follows encouraging early observations among the first participants.

Adults with a confirmed pathogenic or likely pathogenic germline RUNX1 variant, a platelet count of at least 50,000/µL, and no prior diagnosis of MDS or another blood cancer may be eligible. Additional eligibility requirements apply.

Please share with your potentially eligible patients.

Learn more: https://t.co/EtmoFE10RP

[RUNX1 Research Program @RUNX1Research]

Since 2017, RRP has funded and co-funded more than 30 investigators at institutions across the world working to better understand RUNX1-FPD and prevent blood cancer.

None of it happens without community support. As we continue to fund the next generation of research, your donation helps keep this work moving forward.

100% of donations go directly to funding this research: https://t.co/8HAPRfIjM8

[RUNX1 Research Program @RUNX1Research]

Now enrolling: a pilot clinical trial at @UTMDAnderson evaluating low-dose sirolimus (rapamycin) in individuals with RUNX1-FPD.

The study’s primary objective is to assess safety and tolerability. The scientific rationale is based on whether mTORC1 pathway inhibition may support hematopoietic health and potentially reduce blood cancer risk in RUNX1-FPD.

Clinicians are encouraged to review and refer eligible patients here for more information: https://t.co/EtmoFE10RP

[Prof. Nikolai Slavov @slavov_n]

Paying peer reviewers led to faster first editorial decisions — an average of 5.5 working days, down from nearly 38 for unpaid reviews.

The review quality, as judged by handling editors on the basis of helpfulness in making an editorial decision, went up.

1/

[Anupriya Agarwal Lab @LabAgarwal]

@bloodgenes Congratulations Vijay so well deserved 🎉💐

[Anupriya Agarwal Lab @LabAgarwal]

@ASH_hematology Congratulations to all these amazing well deserved recipients 🎉

[Anupriya Agarwal Lab @LabAgarwal]

@ASH_hematology Congratulations to all the recipients 🎉

[Anupriya Agarwal Lab @LabAgarwal]

@beatalleukemia @OSUCCC_James @OSUWexMed Congratulations Uma💐 so well deserved!!!

[Anupriya Agarwal Lab @LabAgarwal]

@DanaFarber Congratulations Andy🎊

[Anupriya Agarwal Lab @LabAgarwal]

@Doulatov_lab Congratulations 🎊

[Anupriya Agarwal Lab @LabAgarwal]

@bloodgenes @lvchosen1 @silvirouskin @Armstrong_dfci @CellPressNews @DanaFarberNews @DanaFarber @BroadMPG @broadinstitute @hhmi_science @BostonChildrens @GauravA_UK @guo_chunjie Congratulations Vijay, looking forward to read it

[Anupriya Agarwal Lab @LabAgarwal]

@AbdelWahablab @CD_AACR Beautiful work congratulations 🎉

[Dr. Anthony Letai @NCIDirector]

At @theNCI, our mission is simple: reduce the burden of cancer.

That means moving faster—from discovery to patient impact—and doing it together.

Follow along as we work to drive the next generation of breakthroughs.

[Anupriya Agarwal Lab @LabAgarwal]

Great mentor and amazing science 🧬

[Jennifer Trowbridge @TrowbridgeLab]

We are actively recruiting a postdoctoral fellow to join our lab @jacksonlab! 😎 Details and link to apply: https://t.co/gH6hOjuBz7

[Jennifer Trowbridge @TrowbridgeLab]

We are actively recruiting a postdoctoral fellow to join our lab @jacksonlab! 😎 Details and link to apply: https://t.co/gH6hOjuBz7

[Anupriya Agarwal Lab @LabAgarwal]

I am honored to receive this grant @OHSUKnight for sirolimus trial in RUNX1-FPD & thankful to @RUNX1Research @ACSNews collaborators Dr. DiNardo @CLachowiez Dr.Lucero, @KellyLBolton Drs. Cantor & Frelinger, patients/families to support our mission of early intervention/prevention

[RUNX1 Research Program @RUNX1Research]

We’re proud to co-fund a new $1.89M LEAP Grant with @AmericanCancer to support an expanded clinical trial at @OHSUKnight and @LabAgarwal.

The study is evaluating a low dose of sirolimus in individuals with RUNX1-FPD to determine safe dosing, an important step in ongoing research toward #bloodcancer prevention and intervention for this high-risk community.

Read more: https://t.co/J9ZyIeP8Xk

[Anupriya Agarwal Lab @LabAgarwal]

I am honored to receive this grant for sirolimus trial in RUNX1-FPD @ACSNews @RUNX1Research & thanks to collaborators Dr. DiNardo @UTMDAnderson @CLachowiez Dr.Lucero, @KellyLBolton Drs. Cantor & Frelinger, patients/families to support our mission of early intervention/prevention

[OHSU Knight Cancer Institute @OHSUKnight]

A new award will enable researchers at @OHSUNews to test an anti-inflammatory drug for patients at heightened risk of developing leukemia due to an inherited mutation in the RUNX1 gene.

@LabAgarwal will serve as the principal investigator at OHSU: https://t.co/7vTmXArTEt

[OHSU Knight Cancer Institute @OHSUKnight]

📣 Save the Date | Oregon Drug Discovery Symposium (ODDS) 2026

The symposium takes place April 8–9, 2026, and will feature scientific talks, discussions, and a poster session, providing a forum for knowledge exchange across disciplines.

Register: https://t.co/naUMxRkXQ3